“…Occupancy of the thrombocyte alpha-2-adrenoccptor leads to an inhibition of adenylate cyclase activity [for review see 17], mediated by an inhibi tory G protein [for review see 7] and causes or facilitates platelet aggregation [4,17], Stimulation of adenylate cyclase activity, leading to elevated cAMP levels, reverses the thrombin-induced increases in thrombocytefree calcium concentrations and exerts thus an antiaggregatory response [21]. A dimin ished platelet adhesiveness, which seems to be closely linked to serum urea nitrogen lev els, is believed to be a cause of uremic bleed ing disorders [6], Additionally, an increase in plasma and thrombocyte cAMP content and of thrombocyte adenylate cyclase activ ity has been observed in uremia [8,19], A possible explanation for this alteration was presented by Brodde et al [1,2], who found a diminished number of thrombocyte alpha-2-adrenoceptors and a shift of the doseresponse curve of (-)-adrenaline, inhibiting adenylate cyclase activity, towards higher concentrations. It was speculated that the decrease in the alpha-2-adrenoceptor num ber was due to elevated catecholamine lev els, possibly because of an impaired neu ronal uptake mechanism in uremia [9], How ever, arguments against a pathophysiological relevance of these findings are furnished by studies of MacFarlane and Stump [12], showing that only about 50% of the throm bocyte alpha-2-adrenoceptors have to be oc cupied to reach maximal inhibition of ade nylate cyclase activity, whereas the decrease in receptor number, observed by Brodde et al [1,2], was only about 20%.…”